Victrix Investment Advisors Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Victrix Investment Advisors purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 23,000 shares of the company's stock, valued at approximately $3,326,000. Johnson & Johnson comprises about 2.4% of Victrix Investment Advisors' portfolio, making the stock its 15th biggest holding.

Other large investors have also recently made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $32,000. Conquis Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $36,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 1.2%

JNJ stock opened at $151.37 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business has a 50 day simple moving average of $156.27 and a two-hundred day simple moving average of $153.85. The company has a market capitalization of $364.20 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.